Keensight Capital-backed Symeres completed the acquisition of DGr Pharma.

Keensight Capital-backed Symeres, a transatlantic contract research organization, completed the acquisition of DGr Pharma, a consultancy and contract research firm specializing in drug development. Financial terms were not disclosed. "This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum," Guillaume Jetten, Symeres CEO.